Dupixent Cancer Lawsuit: What Is a Failure to Warn [2025]

Introduction to the Dupixent Cancer Lawsuit

Dupixent (dupilumab) is a prescription medication used for chronic inflammatory conditions such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. While it offers significant benefits for many patients, recent legal action has focused on allegations that the manufacturers—Sanofi-Aventis and Regeneron Pharmaceuticals—failed to adequately warn about the risk of developing certain cancers, specifically cutaneous T-cell lymphoma (CTCL), in some users.

The core legal issue at the heart of the Dupixent Cancer Lawsuit is known as “failure to warn.” This doctrine requires drug manufacturers to provide healthcare providers and patients with clear, accurate, and timely information about any substantial risks associated with their products. If a company becomes aware—or reasonably should become aware—of a risk like CTCL but does not disclose it through proper labeling or communications, it can be held legally responsible for any resulting harm.

This article focuses on the failure to warn aspect of the Dupixent cancer lawsuit: what constitutes failure to warn under the law, how this applies to Dupixent’s current litigation, and what affected patients need to know if considering legal action.

What Is “Failure to Warn”?

The Legal Duty

Under U.S. product liability law, pharmaceutical companies have an ongoing duty to:

• Investigate all reasonable safety concerns related to their drugs.
• Promptly update warnings and labeling if new risks are identified.
• Adequately inform prescribers and patients of serious or life-threatening adverse effects—even if those risks are rare.

“Failure to warn” occurs when a manufacturer does not meet these obligations. In the context of medications like Dupixent, this can include:

• Insufficient warning labels about potential cancer risks.
• Omitting information about symptoms that could indicate early cancer development.
• Failing to communicate emerging evidence from post-market surveillance or adverse event reports.

Elements Needed for a Lawsuit

To succeed in a failure-to-warn claim related to Dupixent:

1. Duty: The manufacturer had a legal obligation to warn about the risk.
2. Breach: The warning provided was inadequate or missing.
3. Causation: The lack of an adequate warning led directly to patient harm (e.g., delayed diagnosis or improper monitoring).
4. Damages: The patient suffered quantifiable harm—medical costs, lost wages, pain and suffering—as a result.

Failure to Warn in the Dupixent Litigation

Allegations Against Manufacturers

Plaintiffs in current lawsuits allege that Sanofi-Aventis and Regeneron:

• Did not include explicit warnings about cutaneous T-cell lymphoma (CTCL) in prescribing information or patient guides despite accumulating case reports.
• Failed to update labeling or issue “Dear Healthcare Provider” letters after learning of potential links between Dupixent use and increased CTCL incidence.
• Did not ensure that prescribers could recognize early signs of lymphoma potentially masked by improvement in eczema-like symptoms.

Regulatory Oversight

The FDA monitors adverse events reported for all approved medications. If serious risks emerge post-market, manufacturers are expected to:

• Update warnings promptly (including bolded boxed warnings for severe outcomes).
• Communicate new safety information through official channels.
• Proactively conduct additional safety studies if needed.

Failure in any of these areas may constitute negligence under failure-to-warn law.

How Failure to Warn Harms Patients

Without proper warnings:

• Patients may ignore persistent or worsening symptoms that could signal cancer.
• Physicians may misattribute lymphoma-related skin changes as improvements in dermatitis rather than possible malignancy progression.
• Delayed diagnosis can result in more advanced disease at detection, requiring more aggressive treatment with higher risks and worse outcomes.

Compensation in Failure-to-Warn Cases

If a court finds that inadequate warnings contributed to harm, affected patients may be entitled to compensation for:

• Medical expenses (diagnostic tests, treatments)
• Lost income due to illness
• Pain and suffering
• Long-term care needs
• Loss of consortium (for family members)

Final Thoughts on a Failure to Warn

The core focus of current Dupixent lawsuits is whether Sanofi-Aventis and Regeneron failed in their duty to warn about the possible link between Dupixent and certain cancers such as CTCL. If you or someone you know developed lymphoma after using Dupixent and believe there was insufficient warning about this risk, you may have grounds for legal action based on failure-to-warn principles.

Consulting an experienced pharmaceutical litigation attorney can help determine eligibility for compensation—and ensure your rights are protected under evolving drug safety laws.

Research and the Link Between Dupixent and Cancer

Several medical reports and studies including the Nation Library of Medicine have suggested that Dupixent may be tied to an increased risk of CTCL.

• Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: A retrospective cohort study

• • A study published on April 6, 2024 (Hasan et al., 2024), looked at whether people with atopic dermatitis (AD) who were treated with the drug dupilumab had a higher risk of developing cutaneous T-cell lymphoma (CTCL) compared to those who didn’t take the drug. In their first model, which adjusted for age only, they found that people who took dupilumab had a 300% higher risk of getting CTCL compared to those who didn’t (OR 4.10). Even after they adjusted for more factors—like sex, ethnicity, and race, and removed people who had taken certain other immune-suppressing drugs—the risk was still more than two times higher (OR 3.20).

• Increased Risk of Cutaneous T-Cell Lymphoma Development after Dupilumab Use for Atopic Dermatitis

• • A second study using TriNetX data (Mandel et al., 2024) was published in August 2024 and followed a method similar to the first study by Hasan et al. The researchers excluded patients who had other inflammatory diseases or had taken biologic drugs that might be linked to lymphoma.After matching patients by age, race, and sex, they found that people with atopic dermatitis (AD) who were treated with dupilumab had a 350% higher risk of developing cutaneous T-cell lymphoma (CTCL) compared to those who weren’t treated with the drug (RR 4.59).

• Dupilumab and lymphoma risk among patients with asthma: a population-based cohort study

• • In September 2025, a study led by Sheng-Kai Ma and his team looked at the  patients in the United States with asthma who initiated dupilumab or the active comparator (combination therapy with inhaled corticosteroids (ICS) plus long-acting β-agonists (LABA), or ICS/LABA), between 2018 and 2024. After propensity score matching, dupilumab-treated patients were found to have a higher risk of lymphoma (54 versus 43 cases, hazard ratio (HR) 1.79, 95% CI 1.19-2.71), especially T-cell and natural killer (NK)-cell lymphomas (19 versus ≤10 cases, HR 4.58, 95% CI 1.82-11.53).

After adjusting for things like age, gender, income, other health problems, and medicine use, the risk of CTCL was more than 4.5 times higher in the dupilumab group. Dupilumab was also linked to an overall increased risk of any type of lymphoma. When the researchers looked only at patients who had taken their medications for at least 16 weeks, the risk numbers went up even more, especially for combined mature T and NK cell lymphomas, a broader group of cancers including CTCL and other subtypes, which was over 14 times higher for dupilumab users.

• Acceleration of cutaneous T-cell lymphoma following dupilumab administration

• • A 2019 study published in the Nation Library of Medicine, Acceleration of cutaneous T-cell lymphoma following dupilumab administration, showed multiple patients saw CTCL symptoms accelerate while using dupilumab.

• • Case reports warning that Dupixent may “unmask” or worsen hidden lymphomas mistaken for eczema

These findings have pushed doctors to re-evaluate how and when to prescribe Dupixent — especially when patients show unusual skin reactions that don’t improve.

Patient Reports of Cancer Linked to Dupixent

• Patient and Healthcare Reports on FAERS: In addition to the clinical research and studies, the U.S. Federal and Drug Administration’s (FDA),  Adverse Event Reporting System (FAERS) included numerous patient reports and reports from healthcare providers linking Dupixent (dupilumab) to cancer, specifically to multiple types of T-cell lymphoma. FAERS is a vital database that regulators and researchers use to recognize potential drug risks requiring further investigation.

• Reports Confirm Clinical Research: As you will note by visiting FAERS from the button below, the current dashboard shows close to 300 reports of T-cell lymphoma cases among Dupixent patients, which includes confirmed reports of cutaneous T-cell lymphoma (CTCL) and other related and serious conditions. These patient and healthcare reports to the FDA continue to fuel concerns that was addressed in clinical studies, strengthening the need for doctors to closely monitoring patients taking Dupixent.

• The database shows the following type of cases have been reported by patients taking Dupixent or reported by healthcare providers:

• • Cutaneous T-Cell Lymphoma
  • Adult T-Cell Lymphoma/Leukemia
  • T-Cell Lymphoma (general)
  • CTCL, Stage IV
  • CTCL, Stage III
  • Angioimmunoblastic T-Cell Lymphoma
  • CTCL, Stage I
  • Recurrent T-Cell Lymphoma
  • Lymphoma (unspecified)
  • Anaplastic Large Cell Lymphoma (T- and null-cell types)
  • Unclassifiable T-Cell Lymphoma

Volume of Reports:  The vast volume of these reports only provides further evidence that Dupixent may be contributing to serious cancer risks in certain patients.cientific Evidence and Regulatory Action

Scientific studies and reports to the FDA have highlighted a potential link between Dupixent and T-cell lymphomas: 

• FDA Investigation: The FDA is formally investigating the potential safety signal for CTCL linked to Dupixent use. This investigation began in March 2025.

• • Cause of investigation: The FDA’s investigation was prompted by a significant number of adverse event reports linking Dupixent to cutaneous T-cell lymphoma (CTCL).

• • Allegations: A Dupixent Lawsuit against the manufacturers claim they failed to adequately warn patients and doctors about this potential risk.

• • Status: The FDA has not recalled Dupixent, but the investigation is formal and follows a pattern of regulatory actions that may include label revisions. 

• Adverse Event Reports: The FDA’s Adverse Event Reporting System (FAERS) has received hundreds of reports of lymphoma among Dupixent users.

• Increased Risk Studies: Several peer-reviewed studies suggest an increased risk of Dupixent and Cancer.

Who is Eligible for a Dupixent Cancer Lawsuit?

Dupixent Cancer Lawsuit: You may be eligible if you:

• Used Dupixent (dupilumab) as prescribed
• Were later diagnosed with T-Cell Lymphoma, especially Cutaneous T-Cell Lymphoma
• Experienced serious Dupixent side effects or worsening symptoms
• Are within your state’s statute of limitations

 

Compensation in a Dupixent Cancer Lawsuit

If you are eligible for a Dupixent Cancer Lawsuit, a successful plaintiff is entitled to compensatory damages which would include compensation for things such as:

• past and future medical expenses;
• pain and suffering including emotional distress; and
• lost wages and the reduction in your ability to earn an income.

If your case proceeds to trial it is also possible the court could impose punitive damages, intended to punish the defendant for their actions.  Contact Dupixent Cancer Lawyer Timothy L. Miles who can tell you if you are eligible for a Dupixent Cancer Lawsuit and can explain more about the type of damages you are entitled to receive.  (855) 846–6529 or [email protected].

 

If I Was Diagnosed with Dupixent and Cancer, How Do I Get Started?

• Get a Free Case Evaluation: If you or a loved on developed Dupixent and Cancer after taking Dupixent, the most important thing to do now is get a free case evaluation from a Dupixent Cancer Lawyer to see if you qualify for a Dupixent Cancer Lawsuit. These are not typical cases any lawyer can litigate. Contact Dupixent Cancer Lawyer Timothy L. Miles who can tell you if you are eligible for a Dupixent Cancer Lawsuit and can explain more about what will happen next.  (855) 846–6529 or [email protected]. 

• Medical Records Review: The earlier your records are reviewed, the stronger the foundation becomes, especially in cases where the biopsy history is limited or where the initial diagnosis was “eczema” that simply never responded the way it should have. A lawyer experienced in drug litigation can help secure the complete medical file, obtain an independent pathology review if necessary, and establish a clear timeline that courts and juries can follow.

• Time Is of the Essence: If you have a valid case, then it is vital to preserve your rights under the statute of limitations in your state. These deadlines are different in different states, but it normally starts running from the time of diagnosis or from the point when a reasonable person should have realized the connection between the diagnosis and the drug.  Time is of the essence so give Dupixent Cancer Lawyer Timothy L. Miles a call today.

 

Contingency Fee Agreements: No Cost to Hire a Lawyer

• ​​​No Fee:  It does not cost anything to hire a lawyer​ if you are eligible for a Dupixent Cancer Lawsuit. We take all cases on a contingency basis which means we do not get paid unless we win or settle your case.

• Talk with a Lawyer Free of Charge: A lawyer​ can explain the process of a Dupixent Cancer Lawsuit and answer any questions you may have free of charge. The call is free and so is the fee unless we will or settle your case, so call Dupixent Cancer Lawsuit Timothy L. Miles today to see if you may be entitled to significant compensation.